A single plasmid regulated expression vector based upon a mifepristone-inducible two plasmid system, termed pBRES, has been constructed and tested in mice using murine interferon-b (mIFNb) as the transgene. The expression of mIFNb in the circulation was followed by measuring the systemic induction of IP-10, a validated biomarker for mIFNb in mice. Long-term, inducible expression of mIFNb was demonstrated following a single intramuscular (i.m.) injection of the pBRES mIFNb plasmid vector into the hind limb of mice. Induction of mIFNb expression was achieved by administration of the small molecule inducer, mifepristone (MFP). Plasmid DNA and mIFNb mRNA levels in the injected muscles correlated with mIFNb expression as monitored by IP-10 over a 3-month time period. Renewable transgene expression was achieved following repeat administration of the plasmid at 3 months following the first plasmid injection. A dose-dependent increase in expression was demonstrated by varying the amount of injected plasmid or the amount of the inducer administered to the mice. Finally, the pBRES plasmid expressing mIFNb under control of the inducer, MFP, was shown to be efficacious in a murine model of experimental allergic encephalomyelitis, supporting the feasibility of gene-based therapeutic approaches for treating diseases such as multiple sclerosis.
Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the nervous system that results in progressive neuromuscular disability. [1] [2] [3] The current treatment for MS includes IFNb protein therapy that reduces CNS exacerbations by as much as 30%. However, there are side effects from bolus injection of the protein that limit the effectiveness of the drug, including injection site reactions and the formation of neutralizing antibodies. 4, 5 Gene-based delivery of IFNb has been shown to be efficacious in an animal model of MS, experimental autoimmune encephalomyelitis (EAE), and may offer many advantages over bolus protein delivery. [6] [7] [8] Such advantages include a single injection of the gene that provides prolonged therapeutic expression of a natural form of IFNb. In addition, safe (on/off) and controlled dosing of therapeutic levels of IFNb would be achieved using a regulated expression system in which an orally available inducer controls transgene expression.
A variety of small molecule regulated gene expression systems have been described, including those induced by tetracycline, 9 ecdysone, 10 rapamycin, 11 and mifepristone. 12, 13 In general, these systems are two-plasmid systems containing two or three separate expression cassettes, one or two of which express a regulatory molecule, that interacts with a small molecule inducer, and another cassette in which expression of the transgene of interest is controlled by a regulatory DNA region that reacts with the regulatory protein/small molecule complex. The GeneSwitch system is one such system, consisting of two plasmids, the first of which expresses the GeneSwitch transactivator protein (GS), and the second of which carries the target gene of interest that is expressed in response to activated GS. 14 The components of the GeneSwitch system offer advantages for future clinical development over other systems. The GeneSwitch transactivator protein is a fusion protein, consisting of a truncated ligand binding domain from the human progesterone receptor, the transcriptional activation domain from the human NF-kB p65 subunit, and the yeast GAL4 DNA-binding domain (DBD). Except for the 72 residues of the yeast DBD, the remainder of the GeneSwitch protein (631 amino acids) is derived from human sequence, thus reducing the potential for immunogenicity. In addition, the inducer for the GeneSwitch system, mifepristone (MFP), is an orally available approved drug, and there is large safety database that has been established for its use in humans.
A single plasmid regulated expression vector based upon the GeneSwitch (GS), designated 'pBRES', has been constructed and validated in vitro and in vivo using several transgenes, including human IFNb. 15 In this report, murine interferon-b (mIFNb) was incorporated into the pBRES single plasmid system and transgene expression was monitored following i.m. injection of the pBRES mIFNb plasmid DNA into the hind limb of normal C57 mice. Expression of mIFNb was followed by measuring the induction of IP-10, a chemokine that is specifically upregulated by type I IFNs. IP-10 is induced in humans following administration of IFNb protein and has been validated as a biomarker in mice following both mIFNb protein and gene delivery. 16 Inducible expression of IP-10 for over 3 months was demonstrated following i.m. injection of the pBRES mIFNb plasmid vector in mice, with renewable expression following repeat administration of the plasmid. A linear dose-response of transgene expression as monitored by IP-10 induction was obtained with plasmid dose as well as dose of the inducer, MFP.
The pBRES mIFNb plasmid was also tested in a murine model of EAE in which continuous mIFNb expression was induced using MFP pellets implanted in the mice, resulting in a significant decrease in disease scores compared to a null vector-treated group. The pBRES IFNb plasmid vector therefore fulfills many of the key criteria necessary for regulated gene-based delivery to address safety and therapeutic dosing for the treatment of chronic diseases such as MS.
Results

Construction and testing of pBRES mIFN plasmid vectors in vitro and in vivo
Four versions of the single plasmid pBRES vector incorporating mIFNb as the transgene in four different orientations relative to the GeneSwitch transactivator protein gene, pGT23, pGT24, pGT25 and pGT26, were constructed and tested in vitro and in vivo (Figure 1) . Each of the four orientations of pBRES mIFNb ( Figure 1a ) was transfected into murine C2C12 skeletal muscle cells. The media was removed from the cells 24 h after transfection and replaced by fresh media with or without MFP (10 nM), incubated for 24 h, and then assayed for mIFNb protein by enzyme-linked immunosorbent assay (ELISA). The biological activity of the expressed mIFNb protein was confirmed using a murine Type I-interferon receptor reporter gene assay (data not shown). As shown in Figure 1b , very low basal expression was observed in the media with all four pBRES mIFNb vector orientations in the absence of MFP, and high induced levels in the presence of MFP, representing a 350-to 1500-fold induction of mIFNb protein expression.
For comparison with the single plasmid pBRES vectors a control GeneSwitch two-plasmid system (2 plasmid GS) expressing mIFNb was also tested in C2C12 cells. A two-to fourfold greater level of expression was observed with the pBRES vectors than with the control GS two-plasmid system. The expression level of mIFNb from the pBRES vectors following MFP induction was about 20-40% of that driven by the strong, constitutive cytomegalovirus (CMV) promoter.
Each of the pBRES mIFNb plasmid vectors was also tested in C57Bl/6 mice. Ten mice per plasmid group were administered i.m. injections of the pBRES plasmid in the hind limb with electroporation on day 0, and five mice from each group were treated with MFP (0.33 mg/ kg, by intraperitoneal (i.p.) injection) on days 7-10. Serum from all mice was collected 6 h after the last MFP administration on day 10, and assayed for IP-10 by ELISA. IP-10, a validated biomarker for mIFNb in C57Bl/6 mice, 16 was chosen as an end point to monitor mIFNb transgene expression in vivo because serum effects precluded accurate detection of mIFNb protein by an ELISA. The results shown in Figure 1c demonstrate that all four orientations show very low basal IP-10 levels in the mice not administered MFP administration and high induced levels in the mice treated with MFP. Control naïve animals that did not receive plasmid injections or electroporation (EP) were assayed for IP-10 and expressed approximately 50 pg/ml. No IP-10 induction above background was observed at day 10 in animals injected with either null plasmid DNA or a plasmid-expressing mouse secreted alkaline phosphatase (mSEAP) with EP (data not shown). All four single plasmid pBRES mIFNb vectors exhibited approximately the same level of induction as the two-plasmid vector. Contrary to what was observed in vitro, all four pBRES mIFNb plasmids, including the two-plasmid GS, showed higher expression, as determined by IP-10, than a mIFNb plasmid driven by the constitutive CMV promoter. The pGT26 pBRES mIFNb vector was chosen as the preferred vector for all of the subsequent in vivo studies based upon the high induction level and low basal activity observed in vivo.
Long-term, regulated expression of mIFNb-induced IP-10 using pBRES mIFNb plasmid
The pBRES mIFNb plasmid DNA (pGT26) was electroporated into the hind limb of mice and MFP was Figure 1 (a) Four orientations of the pBRES murine interferon b (mIFNb) expression vectors. All of the elements of the two-plasmid GeneSwitch were combined onto a single plasmid as described. 15 The constructs, pGT23, pGT24, pGT25 and pGT26 are the pBRES single plasmid vectors containing the GeneSwitch transactivator and mIFNb coding sequences on the same plasmid in four different orientations. The GeneSwitch responsive Â 6 Gal4 sites are located upstream of a multiple cloning site (MCS) and human growth hormone (hGH) poly(A) element. The mIFNb gene has been inserted into the MCS as shown in each vector. (b) Regulated expression of mIFNb in vitro using four orientations of the pBRES mIFNb plasmid. Murine C2C12 myoblasts were transfected with either the two plasmid GeneSwitch system (twoplasmid GS), one of the four orientations of the pBRES mIFNb plasmids (pGT23, pGT24, pGT25, pGT26) or a plasmid expressing mIFNb under the control of the constitutive cytomegalovirus (CMV) promoter/enhancer (CMV). Twenty-four hours post-transfection media from each well was replaced with fresh media with or without MFP (10 nM final concentration). Media was collected at 48 h post transfection and murine IFNb protein concentration was determined by enzyme-linked immunosorbent assay (ELISA). The fold induction of mIFNb detected in the media over uninduced levels is indicated for each of the regulated plasmids tested. The average of three independent transfections is shown. Error bars represent the mean of the three transfections7s. animals that had not received the inducer (data not shown). IP-10 levels returned to background within 72 h following the last dose of MFP (data not shown). Peak IP-10 induction levels at 3 months post-injection were approximately 30% of the initial peak levels. The pBRES mIFNb plasmid was re-administered 3 months after the first injection and IP-10 expression was restored to the level observed following the first injection. The same pattern of decreasing expression was observed following the second plasmid injection over the next 3 months. A third injection of the pBRES plasmid was performed at 6 months. Expression was restored to the levels observed with the first two injections of plasmid and inducible expression was demonstrated for the remaining 2 months of the study.
In summary, long-term, inducible expression was demonstrated using a pBRES mIFNb plasmid in mice and repeat administration of the pBRES mIFNb plasmid vector resulted in renewed expression to the levels observed from the initial plasmid administration.
Correlation of IP-10 biomarker response with mIFNb RNA expression in pBRES mIFNb injected mouse muscles
A time-course study was performed to investigate how IP-10 induction levels correlated with the level of mIFNb mRNA expression and plasmid vector DNA levels in the injected muscles ( Figure 3 ). Mice were injected with pBRES mIFNb plasmid and then killed at various time points immediately following MFP induction over a 4-month time period. At each time point IP-10 was measured in addition to mIFNb RNA and plasmid vector DNA in the injected muscles of the mice. After the 4-month period (day 133) IP-10 induction diminished to approximately 30% of the initial levels detected immediately following plasmid injection (day 11). Quantitative RT-PCR analysis of total RNA extracted from the plasmid injected muscles of the mice at each time point showed a decrease from 2.3 Â 10 6 copies per mg total RNA (day 11) to 1.9 Â 10 5 copies/mg total RNA (day 133), representing approximately 11% of the initial level. Plasmid vector DNA from the same muscles decreased from 1.1 Â 10 6 copies/mg total DNA (day 11) to 1.9 Â 10 4 copies/mg total DNA (day 144), representing approximately 3% of the initial level post-injection. These data suggest that the decrease in transgene expression level as monitored by mIFNb-induced IP-10 levels directly correlates with the amount of vector DNA remaining and transgene mRNA expressed in the muscles of the pBRES mIFNb plasmid injected mice.
Continuous expression of mIFNb-induced IP-10 using pBRES mIFNb plasmid
We wished to examine the basal activity or 'leakiness' of the pBRES mIFNb plasmid in the absence of the inducer over time. Mice were injected with the pBRES mIFNb plasmid and assayed for IP-10 every 14 days for 38 days total without any exposure to the inducer. Very low IP-10 induction was observed in the absence of inducer compared to naïve animals ( Figure 4 ). There was no significant increase in the basal level of IP-10 over the time course of the study, indicating no measurable 'leakiness' of the pBRES system.
In the same study, we wished to examine the effect of continuous exposure to the inducer on IP-10 levels over time. As shown in Figure 4 , with daily administration of MFP to mice, IP-10 expression was maintained at a high level over the 45-day study. The induced IP-10 levels decreased by approximately 35% over the course of the study, consistent with the slow loss of plasmid DNA from the muscles shown previously (Figure 3 ).
Plasmid and inducer dose-response using pBRES mIFNb
Two sets of dose-response studies in mice were performed using the pBRES mIFNb plasmid, either by varying the amount of plasmid DNA injected and administering a fixed amount of inducer or by varying the amount of inducer administered to mice that were injected with a fixed amount of plasmid. Serum IP-10 in Regulated expression of IFNb in mice RN Harkins et al addition to vector DNA and mIFNb mRNA in the injected muscles were measured immediately following MFP induction in both studies. The results from the first study in which mice were injected with either 50, 150 or 300 mg of pBRES mIFNb plasmid DNA, administered MFP on days 7-10, and killed on day 11 are shown in Figure 5 . A dose-dependent increase in IP-10, vector DNA level and mIFNb RNA expression was observed with increasing amounts of plasmid. There did not appear to be a saturating effect on IP-10 level or mIFNb mRNA expression at the highest level of plasmid DNA (300 mg) injected into the animals. The MFP dose-response study was performed by injecting groups of mice with a fixed amount of the pBRES mIFNb plasmid (250 mg), administering each group a different amount of inducer (from 0 to 1.0 mg/ kg MFP by IP injection) on days 7-10, and then assaying for IP-10 on day 11 by tail bleed. A dose-dependent induction of IP-10 with increasing amounts of MFP was observed ( Figure 6 ). The response was linear over at least 2 logs of the MFP administered, with an approximate EC 50 of 0.05 mg/kg. Dose-dependent levels of IP-10 were maintained after two additional cycles of induction, albeit at diminished levels (data not shown). The induction levels decreased to approximately 30% of the initial levels after 2 months, consistent with the data shown previously (Figures 2 and 3) . The animals were re-injected with 250 mg of pBRES plasmid on day 77, the MFP dose-response was repeated, and the animals were assayed again for IP-10 on day 88. The levels of the IP-10 response at each MFP dose upon re-injection of the pBRES mIFNb plasmid were very similar to the levels observed following the first plasmid injection and MFP dosing regimen.
Efficacy of pBRES mIFNb gene delivery in EAE model
Experimental allergic EAE is a neuroinflammatory disease animal model that mimics many of the symptoms of MS. Previous studies have shown that IFNb is efficacious in rodent models of EAE using both protein 17, 18 and local gene delivery. [6] [7] [8] The vectors used previously for the mIFNb gene-based efficacy studies incorporated the CMV promoter or a tissue-specific promoter driving constitutive expression of the IFNb transgene. We wished to demonstrate efficacy of IFNb in an EAE model using the pBRES plasmid, in which IFNb expression was controlled by MFP induction. Figure 7a shows the validation of the murine active EAE model in SJL mice in which the animals were injected with PLP/ pertussis on day 1 to initiate disease and then treated with mIFNb protein (100 000 or 300 000 units) by SC injection every other day throughout the course of the 25-day study. Based upon the clinical scores, both concentrations of mIFNb protein significantly reduced the severity of the disease compared to vehicle treated animals. For IFNb gene delivery the pBRES plasmid (either null vector or vector encoding mIFNb) was administered by i.m. injection to the hind limbs of the animals on day-7. Figure 7b demonstrates that in the absence of inducer neither vector had any effect on the severity of disease compared to untreated animals. However, following vector administration on day-7 and implantation of slow release MFP pellets on day-2 of the study, the pBRES mIFNb plasmid treated animals plus MFP induction displayed a significant delay in the onset of disease (P ¼ 0.02) as well as a significant decrease in the overall severity of disease scores (P ¼ 0.05), compared to the pBRES null vector plus MFP control group (Figure 7c ). During the study (on day 8) and at the end of the study (on day 23) hind limb muscles from a subset of the mice injected with either the pBRES null vector or the pBRES mIFNb vector were analyzed for mIFNb RNA levels by quantitative RT-PCR. Figure 7d shows that endogenous mIFNb RNA levels in the null vector injected muscles were near or only slightly elevated above the lower limit of quantitation of the assay (100 copies mIFNb RNA per mg total RNA), while the pBRES mIFNb plasmid injected muscles expressed between 7.9 Â 10 5 copies (day 8) and 1.4 Â 10 5 copies (day 23) of mIFNb RNA per mg of total RNA. The results show high levels of mIFNb expression in the pBRES mIFNb injected muscles following MFP induction, leading to a significant decrease in EAE disease onset and severity.
Discussion
Interferon-b protein therapy has been successfully used to treat MS patients for over 15 years and is considered a Regulated expression of IFNb in mice RN Harkins et al front-line treatment for the relapsing remitting form of the disease. 19 It has recently been shown that early treatment of patients with IFNb-1b significantly delays the progression of MS. 20 However, there are issues relating to the frequent administration of IFNb protein that have limited its effectiveness, including injection site reactions and the formation of neutralizing antibodies. 5 Gene-based delivery of IFNb could offer several advantages over protein delivery in this regard. A single injection of the gene could provide efficacious levels of the natural form of the protein expressed in the patient's own cells, and regulated levels of the protein could be expressed systemically within a defined therapeutic window. IFNb gene delivery has been shown to be efficacious in experimental autoimmune EAE, an animal model of MS. [6] [7] [8] Schaefer et al. 7 showed that a single i.m. injection of a nonviral plasmid encoding mIFNb under the control of a CMV promoter was effective in significantly decreasing disease severity in a murine model of EAE.
For gene therapy to be a viable method in treating a chronic disease the delivery vector must be capable of providing therapeutic levels over several months, perhaps years. Long-term treatment of patients with gene therapy will most likely require repeat administration of the vector. Nonviral plasmid DNA vectors have been shown to be safe and relatively non-immunogenic compared to viral vectors, and unlike viral vectors, 21 In addition, plasmid vectors can be administered by i.m. injection, and skeletal muscle is a convenient site that is safe and routinely used for drug delivery. The post-mitotic muscle cell is well suited as a host cell for the expression of a therapeutic transgene. Although naked plasmid DNA is not taken up readily by muscle cells, electroporation has been shown to improve plasmid DNA uptake into skeletal muscle by as much as 100-fold and is clinically feasible. [22] [23] [24] The pBRES expression vector contains all the components of a regulated gene expression system combined on a single plasmid, thus providing the safety, ease of manufacturing, and simplicity of a nonviral plasmid delivery vector. Low basal activity and high induction levels have been demonstrated with a number of transgenes in animal models. 15 The small molecule inducer, MFP, is an orally available, approved drug and has been shown to be safe and well tolerated in the doses that would be used to achieve therapeutic levels in humans. 25 MFP is also in clinical testing for other indications and has been shown in numerous studies to be safe and well tolerated. 26 The pBRES plasmid vector has been constructed with mIFNb as the transgene, and all four orientations were evaluated in vitro and in vivo for basal activity in the absence of inducer and peak expression in the presence of inducer. All four pBRES mIFNb plasmids demonstrated equal or better performance than the two-plasmid GS system. In vitro in C2C12 cells, a constitutively expressing CMV driven mIFNb plasmid expressed significantly greater levels of mIFNb than the pBRES mIFNb plasmids, while in mice the pBRES plasmids and the two-plasmid GS generated a significantly higher IP-10 response than the CMV mIFNb plasmid. Although we do not fully understand this observation, similar data were obtained when human IFNb was tested as the transgene in the pBRES system. 15 In this case, direct hIFNb determination by ELISA was used to measure transgene expression both in vitro and in vivo. We have also observed during the evaluation of alternative promoters for pBRES, in which the skeletal muscle actin promoter was replaced (for example, with human ubiquitin B promoter or chimpanzee EF-1a promoter) the relative levels of transgene expression among the different promoters can differ from in vitro to in vivo testing (unpublished data).
For the in vivo studies in mice, IP-10 levels were used to monitor mIFNb expression. IP-10 is a member of the chemokine family of cytokines and is induced in a variety of cells in response to interferons. Although IP-10 is known to be activated by inflammatory cytokines, 27 it has also been shown in recent studies to be upregulated in ex vivo IFNb-treated PBMCs (peripheral blood mononuclear cells) and in IFNb-treated patients. [28] [29] [30] Doseresponse studies with the mIFNb protein and gene delivery in C57Bl/6 mice have shown that there is a rapid induction of IP-10 following bolus administration of protein and following gene delivery using either plasmid or AAV1 vectors. 16 The pBRES plasmid orientation corresponding to pGT26 was selected for all subsequent in vivo studies because it displayed the best overall performance (lowest basal activity, highest IP-10 response with MFP). Using this vector, inducible mIFNb expression based upon IP-10 response was demonstrated in mice for more than 3 months with the capability to renew expression with repeat administration. The loss of IP-10 expression over time correlated with the reduced levels of vector DNA and mIFNb mRNA remaining in the injected muscles, indicating that the loss in expression is not due to transcriptional silencing or desensitization of the IP-10 response to IFNb.
The exact mechanism for the loss of plasmid DNA and associated decrease in mIFNb transgene expression from the transfected muscle cells is not clear. We have not analyzed for the formation of neutralizing antibodies against the GeneSwitch transactivator protein or against mIFNb protein in the sera of mice treated with the pBRES mIFNb plasmid. It is possible that the loss of plasmid DNA observed over time could be facilitated by an immune response against the transfected muscle target cell. We have been able to renew expression levels to the level observed with the first injection, which might not be expected if antibodies against IFNb were generated following the initial plasmid injection.
Studies have shown that the electroporation conditions and that the components within the plasmid DNA (for example, unmethylated CpG motifs from bacterial derived plasmid DNA) can generate a potent innate immune response that may affect the viability of the transfected muscle cell and transgene expression. For example, it is well known that plasmid electroporation of muscle results in varying degrees of muscle damage followed by an influx of inflammatory cells that peaks around 7 days and returns to normal within 2 weeks. 31 We have performed histological analysis of transfected mouse muscles at days 7 and 14 following plasmid injection with electroporation with either a null plasmid or a plasmid expressing mIFNb. There is muscle damage associated with the electroporation and infiltration of mononuclear cells at the site of the injection for both groups at day 7, but we have observed no obvious differences in the amount of damage or inflammatory infiltrates between the null plasmid and mIFNb plasmid injected muscles. At day 14 both groups of plasmidinjected muscles have similar patterns resolution of the inflammation at the injection site (unpublished data).
We have recently completed gene expression array studies to examine the effects of plasmid delivery and electroporation on the induction of inflammatory response genes in injected mouse muscle. 32 The results show that the nature of the plasmid as well as the transgene have an effect on the level of induction of these genes in the injected muscle. i.m. injection of a standard null plasmid with electroporation results in an increase in inflammatory response genes at the site of injection that peaks at day 5 and nearly resolves by day 10. The presence of mIFNb as a transgene causes a subset of these genes to increase significantly over those induced by a null plasmid, particularly CD69, a marker for activated T cells. This enhanced immune response by the mIFNb transgene may have an effect on the persistence of expression from the target muscle cells. The extent to which pBRES-driven mIFNb transgene expression and this enhanced immune response affects plasmid and transgene expression persistence over time will require further examination. Studies using CpG-free plasmids have shown improved transgene expression and duration, [33] [34] [35] and modification of electroporation conditions 36 Future studies directed toward the optimization of these parameters should lead to improvements in the level and duration of transgene expression using plasmid delivery to skeletal muscle.
A linear dose-response for IP-10 expression with pBRES mIFNb could be achieved by MFP dosing in mice and this could also be reproduced following repeat administration of the plasmid after 3 months. The EC 50 for induction by MFP was approximately 0.05 mg/kg, consistent with values that have been obtained for the two-plasmid GeneSwitch. 37 Since the therapeutic dose of MFP for its use as an abortifacient in humans is 600 mg, or approximately 10 mg/kg, the dosage for MFP in humans as an inducer of the pBRES expression system is at least two orders of magnitude lower than the abortifacient dose. Moreover, a large safety database exists demonstrating the safety of low doses of MFP administered over several months in humans. 25 It is known that MFP at low doses does have a pharmacological effect as a contraceptive in women. However, we do not believe this would pose a problem with its use as an orally available inducer of a pBRES IFNb gene therapy in female MS patients because women patients receiving IFNb protein therapy are advised not to bear children during IFNb treatment.
In the murine acute EAE model of MS a single administration of the pBRES mIFNb plasmid plus MFP was shown to decrease significantly the onset of disease as well as decrease the overall severity of the disease scores. Because of the relatively short duration of the acute EAE model (23 days), we were not able to assess the efficacy of mIFNb gene delivery in a more chronic form of the disease that is similar to MS in humans. Future testing of the pBRES mIFNb vector in a chronic relapsing EAE model would also provide an opportunity to evaluate pulsatile induction of mIFNb during the exacerbation periods of the disease that also occur in MS patients.
Materials and methods
pBRES mIFNb plasmid construction and in vitro testing pGER101 (CMV-mIFNb). The murine IFNb (mIFNb) full-length cDNA (GenBank accession number BC119397) was amplified by PCR and SalI and NotI restriction enzyme sites added at the 5 0 and 3 0 ends. The fragment was digested with SalI and NotI and inserted into the SalI and NotI sites of plasmid vector pgWIZ, 7 resulting in plasmid vector pGER101.
pGT23-26 (pBRES-mIFNb). pGER101 was digested
with SalI, blunt-ended with Klenow DNA polymerase, ligated to SpeI linkers and digested with SpeI plus NotI. The resulting DNA fragment containing the mIFNb gene was ligated to SpeI/NotI-digested pGT1, pGT2, pGT3 and pGT4 to create pGT23, pGT24, pGT25 and pGT26, respectively. 15 The two GeneSwitch-related plasmids used for in vitro and in vivo validation studies (two plasmid GS) were pGS1694 (Nordstrom steroids), encoding the GeneSwitch transactivator protein and pGER127, encoding the mIFNb protein. pGER127 is identical to pEP1666, with the EPO gene replaced by the mIFNb gene (Nordstrom 14 ). Plasmid preparations used Qiagen (Valencia, CA, USA) mini, maxi or giga-prep kits (endotoxin free). Restriction enzymes were purchased from New England BioLabs (Beverly, MA, USA).
Undifferentiated mouse skeletal muscle C2C12 cells were transfected with 0.4 mg of plasmid per well of a 12-well plate with FuGene6 (Roche) and 24 h post-transfection media from each well was replaced with fresh media with or without MFP (10 nM final concentration). Media was collected at 48 h post-transfection for assay of mIFNb protein and functional activity.
mIFNb, IP-10 assays
Murine IFNb protein in transfected cell media was determined by ELISA (PBL Biomedical Labs, Piscataway, NJ, USA) and the biological activity of the expressed protein was verified using a reporter gene assay in murine L929 cells expressing the murine type I IFN receptor and transfected with a type I IFN-responsive reporter plasmid. 38 Purified recombinant mIFNb protein was used as a standard (specific activity ¼ 2.0 Â 10 8 IU/ mg). 7 Serum samples were analyzed for murine IP-10 levels using a commercial ELISA kit (R&D Systems, Minneapolis, MN, USA).
pBRES mIFNb testing in mice
Adult male C57Bl/6 (Jackson Laboratory, Bar Harbor, ME, USA) were used for the experiments. All mice were housed under controlled temperature (241C) and lighting (14:10 h light-dark cycle) conditions with free access to food and water. The experiments were conducted according to protocols approved by the Animal Care Committee at Berlex Biosciences, in agreement with the recommendation of the American Association for the Accreditation of Laboratory Animal Care. During the in vivo gene transfer, all of the animals were anesthetized with 1.5% isoflurane inhalation.
Mice were administered i.m. injections of 250 mg plasmid DNA in PBS per mouse in a volume of 150 ml. The DNA was injected 25 ml into the tibialis muscle and 50 ml into the gastrocnemius muscle of each hind leg. The muscles were then electroporated with caliper electrodes (Inovio Biomedical Corp., San Diego, CA, USA 8 pulses at 200 V/cm, 1 Hz, 20 ms/pulse). Mice were administered MFP at 0.33 mg/kg by i.p. injection (100 ml of 0.083 mg/ml in sesame oil) and bled by tail nick. Blood was collected in microtainer tubes containing no anticoagulant, allowed to clot at room temperature for 30 min, and the serum was separated by centrifugation (5000 r.p.m., 5 min in a microfuge) and collected.
pBRES testing in murine EAE model
Eight-week-old female SJL mice (Jackson Labs, Bar Harbor, ME, USA) were immunized on day 1 of the study with a 0.1 ml subcutaneous (SC) injection containing 150 mg Proteolipid Protein (PLP) 139-151 in complete Freund's adjuvant, supplemented with 200 mg M tuberculosis H37Ra. Immediately after immunization, all mice received a 0.1 ml i.p. injection of pertussis toxin. Two days after immunization, all mice received a second i.p. injection of pertussis toxin. Mice were housed under standard conditions, with food and water available ad libitum and a schedule of 12 h of light and The positive control used for this study was Prednisolone, 2.5 mg/kg (Sigma, St Louis, MO, USA) administered by i.p. injection twice daily, beginning on day 1, until the end of the study.
For mIFNb protein delivery, the mice were given SC injections of purified recombinant mIFNb protein every other day, starting on day 1 of the study (100 000 or 300 000 IU per animal per injection in 100 ml vehicle buffer). Recombinant mIFNb protein was purified 7 and stored at À801C in vehicle buffer (50 mM sodium acetate, pH 5.5, 150 mM sodium chloride and 5% propylene glycol) before use. The specific activity of the purified protein was 2 Â 10 8 international units (IU) per mg. For mIFNb gene delivery, mice received an i.m. injection on day-7 of either pBRES null vector plasmid DNA with EP, or pBRES mIFNb vector plasmid DNA with EP. Each animal was injected bilaterally with PBS or a total of 200 mg plasmid DNA (100 mg per limb) in 120 ml PBS (20 ml into the tibialis muscle and 40 ml into the gastrocnemius muscle of each hind limb). Immediately following injection, the muscles were electroporated with a caliper electrode (8 pulses at 200 V/cm, 1 Hz, 20 ms/ pulse) using a BTX ECM 830 EP instrument supplied by (Inovio Biomedical Corp., San Diego, CA, USA). Induction of expression was initiated on dayÀ2 by administration of a single MFP pellet (2.5 mg/60 day release pellet, Innovative Research of America, Sarasota, FL, USA) by SC injection.
The mice were scored daily based on the following scoring system: 0 ¼ normal; 1 ¼ limp tail; 2 ¼ difficulty righting; 3 ¼ incomplete paralysis of one or both hind limbs; 4 ¼ complete paralysis of one or both hind limbs, or hind limbs mobile but drag; 5 ¼ complete paralysis of both hind limbs and weakness/paralysis of forelimbs, moribund or dead. Moribund mice were euthanized. Statistical analysis was performed by applying a MannWhitney U-test on the cumulative clinical scores obtained from each animal in each group of the study (n ¼ 10 animals per group). An additional three mice were added to the pBRES null and pBRES mIFNb for mIFNb RNA analysis.
mIFNb RNA and vector DNA Q-PCR analysis
The injected muscles were excised and placed in RNA later buffer (Qiagen, Valencia, CA, USA) and then homogenized in RLT buffer (Qiagen) using a bead beater. Two volumes of water and proteinase K (PK) were added to the homogenate followed by incubation at 551C for 15 min and centrifugation to pellet precipitated protein. Total RNA was purified from an aliquot of the PK-treated lysate using RNeasy mini columns (Qiagen). RNA samples were treated with DNase I before analysis to remove any contaminating DNA, as described by the manufacturer (Qiagen). Total DNA was purified from an aliquot of the PK treated lysate using the RNA/DNA kit (Qiagen).
The copy number of mIFN mRNA in total RNA was determined by real time quantitative RT-PCR using TaqMan chemistry. Each assay contained 0.2 mM each primer and 0.1 mM probe (F primer: CTGGAGCAGCT GAATGGAAAG; R primer: TCCGTCATCTCCATAGG GATCT; probe: 6FAM-TCAACCTCACCTACAGGGCG GACTTC), 500 ng of total RNA, 1 Â PCR master mix and 1 Â reverse transcriptase and RNase inhibitor mix (Applied Biosystems, Foster City, CA, USA) assembled in 96-well plates. The plates were run in a ABI 7000 sequence detection instrument with the following cycle conditions; 481C 30 min, 951C 10 min, 40 cycles of 951C 15 s, 601C 1 min. Serially diluted synthetic RNA of known copy number made by in vitro transcription of the mIFN cDNA was assayed in each plate to generate a standard curve from which the copy number of unknown samples was determined. The Q-RT-PCR assay was linear over 6 logs (10 1 -10 7 copies) with a lower limit of quantitation (LOQ) of 100 copies per mg RNA. Equal amounts (usually 500 ng) of each muscle RNA was assayed and the data expressed as copies of mIFNb RNA per mg of total muscle RNA. Q-RT-PCR for mouse GAPDH demonstrated that all RNA samples were intact.
Plasmid DNA copy number was determined by real time quantitative PCR using TaqMan chemistry and primers and probe directed against the GeneSwitch coding region. Each assay contained 0.3 mM each primer and 0.1 mM probe (F primer: CACTGGATGCTGTTGCT CTCC; R primer: AATCTCTGGCTTAGGGCTTGG; probe: 6FAM-TCATTTGGAACGCCCACTGGCTGT), 500 ng of total DNA, and 1 Â PCR master mix (Applied Biosystems) assembled in 96-well plates. The plates were run in a ABI 7000 sequence detection instrument with the following cycle conditions: 501C 2 min, 951C 10 min, 40 cycles of 951C 15 s, 601C 1 min. Serially diluted linear plasmid DNA of known copy number containing the GS coding region was assayed in each plate to generate a standard curve from which the copy number of unknown samples was determined. The lower limit of quantitation was 50 copies of vector DNA per mg DNA.
